{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T21:59:29Z","timestamp":1785707969385,"version":"3.56.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2018ZX09736002"],"award-info":[{"award-number":["2018ZX09736002"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40261-025-01518-8","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T16:27:44Z","timestamp":1767716864000},"page":"143-157","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Population Pharmacokinetics of SCT510 (a Bevacizumab Biosimilar) and Avastin\u00ae in Healthy Subjects and Patients with Non-squamous Non-small Cell Lung Cancer"],"prefix":"10.1007","volume":"46","author":[{"given":"Qianqian","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhuan","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6765-6651","authenticated-orcid":false,"given":"Liangzhi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"1518_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102017","volume":"86","author":"G Josep","year":"2020","unstructured":"Josep G, Herbert IH, Alan BS, et al. Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020;86:102017.","journal-title":"Cancer Treat Rev"},{"key":"1518_CR2","unstructured":"US Food and Drug Administration. Avastin\u00ae (bevacizumab): US prescribing information. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125085s332lbl.pdf. Accessed May 2020."},{"key":"1518_CR3","unstructured":"European Medicines Agency (EMA). Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/avastin#authorisation-details-section. Accessed Jun 2020."},{"key":"1518_CR4","unstructured":"European Medicines Agency, Committee for medicinal products for human use (CHMP). Guideline on similar biological medicinal products. CHMP\/437\/04 Rev. 2014 October 23. Guideline on similar biological medical products (30 April 2015). Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-rev1_en.pdf. Accessed 23 Dec 2025."},{"key":"1518_CR5","unstructured":"National Medical Products Administration (NMPA). An bei Zhu\u00ae label (public announcement date 6 August 2024). Available from: https:\/\/www.cde.org.cn\/main\/xxgk\/postmarketpage?acceptidCODE=c484577def60e567b48ee9a6083dc66e. Accessed 23 Dec 2025."},{"key":"1518_CR6","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40268-023-00424-8","volume":"23","author":"W Jing","year":"2023","unstructured":"Jing W, Guolan W, Liangzhi X, et al. A randomized, double-blind, parallel-controlled phase I study comparing the pharmacokinetics, safety, and immunogenicity of SCT510 to bevacizumab (Avastin\u00ae) in healthy Chinese males. Drugs R&D. 2023;23:175\u201383.","journal-title":"Drugs R&D"},{"issue":"11","key":"1518_CR7","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1007\/s12325-024-02965-z","volume":"41","author":"C Ying","year":"2024","unstructured":"Ying C, Zhanyu P, Lin W, et al. Efficacy and safety of biosimilar SCT510 compared with bevacizumab for the first-line treatment of advanced non-squamous non-small cell lung cancer: a randomized, double-blind, phase III study. Adv Ther. 2024;41(11):4032\u201348.","journal-title":"Adv Ther"},{"key":"1518_CR8","doi-asserted-by":"crossref","unstructured":"Joannes AAR, van TD, FMLS, et al. Use of population approach non-linear mixed effects models in the evaluation of biosimilarity of monoclonal antibodies. Eur J Clin Pharmacol. 2016;72:1343\u201352.","DOI":"10.1007\/s00228-016-2101-6"},{"key":"1518_CR9","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/j.1552-4604.1997.tb04326.x","volume":"37","author":"IE Ene","year":"1997","unstructured":"Ene IE. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol. 1997;37:486\u201395.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"1518_CR10","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1023\/A:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28(5):481\u2013504.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"5","key":"1518_CR11","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00280-007-0664-8","volume":"62","author":"L Jian-Feng","year":"2008","unstructured":"Jian-Feng L, Rene B, Steve E, et al. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol. 2008;62(5):779\u201386.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"1518_CR12","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00280-016-3079-6","volume":"78","author":"H Kelong","year":"2016","unstructured":"Kelong H, Thomas P, Mathilde M, et al. Population pharmacokinetics of bevacizumab in cancer patients with external validation. Cancer Chemother Pharmacol. 2016;78(2):341\u201351.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"1518_CR13","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00280-019-03946-8","volume":"85","author":"SWL Cheryl","year":"2020","unstructured":"Cheryl SWL, Kevin S, Carol C. Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin\u00ae) in patients with advanced non-squamous non-small cell lung cancer. Cancer Chemother Pharmacol. 2020;85(3):487\u201399.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"1518_CR14","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.clim.2006.09.001","volume":"122","author":"K Jonghan","year":"2007","unstructured":"Jonghan K, Willam LH, John MR, Clark LA. Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model. Clin Immunol. 2007;122(2):146\u201355.","journal-title":"Clin Immunol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01518-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-025-01518-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01518-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T04:35:24Z","timestamp":1770179724000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-025-01518-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1518"],"URL":"https:\/\/doi.org\/10.1007\/s40261-025-01518-8","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Qianqian Hong, Yuhuan Jiao, Dongyang Li, Hongyun Ma, Kun Wu, and Liangzhi Xie are employees of Sinocelltech Co., Ltd. and have stock ownership and\/or potential stock option interests in the company. All authors have no conflicts of interest that are directly relevant to content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"The trial was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of the First Affiliated Hospital, Zhejiang University School of Medicine (SCT510NSCLC01, approval no. 2017-EC-244) and Jilin Province Cancer Hospital Institutional Review Board (SCT510-A301, approval no. 201810-070-01).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Patients provided written informed consent prior to trial enrollment.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The data presented in this study are available on request from the corresponding author because of patient confidentiality.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The NONMEM control streams for the final PopPK model and its associated output is provided in the ESM.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors contributed to the study conception and design. Data curation and analysis were performed by QQH and YHJ. The first draft was developed by QQH. All authors have read and agreed to the published version of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}